Foghorn Therapeutics Inc (FHTX) financials
Foghorn Therapeutics revenue and earnings by year
Foghorn Therapeutics's revenue was $30.9 million in the fiscal year to December 31, 2025, up 36.8% from the year before. Net income was -$74.3 million, -240.3% of revenue. Since the fiscal year to December 31, 2020, revenue has grown 135.2% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 6 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
| Revenue | 31 | 23 | 34 | 19 | 1 | 0 |
| Revenue growth | 36.8% | -33.8% | 77.6% | 1357.8% | 206.7% | — |
| Operating income | -88 | -103 | -108 | -117 | -101 | -69 |
| Operating margin | -284.8% | -454.3% | -315.9% | -609.2% | -7637.1% | -15937.4% |
| Net income | -74 | -87 | -98 | -109 | -101 | -69 |
| Net margin | -240.3% | -383.2% | -288.2% | -566.3% | -7681.6% | -16000.0% |
| Diluted EPS | -$1.18 | -$1.58 | -$2.34 | -$2.62 | -$2.73 | — |
| Free cash flow | -86 | -101 | -119 | 192 | -54 | -47 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open FHTX in Markets.
See also: FHTX returns
No forecast, no recommendation. This page describes Foghorn Therapeutics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.